26 March 2014

Who's Doing FBLD, 2014 Version

It's been a while since we updated this list.  The first list had 24 companies, the second 44.  From 2011 to now, what's changed?

I have divided the list into (primarily) providers of services and pharmaceutical companies. This does not mean that that providers don't do their own discovery, or work in a mixed-model.  I have annotated those companies which were not previously on the list.  Please note that this does not necessarily mean they were not doing FBDD previously, they just were not listed.If we missed someone, let us know and we will update the post.

Providers:
Ancorex  (New 2014)
Beactica
Biodesy  (New 2014)
Biofocus(Galapagos)  Acquired by Charles River Laboratories
Biosensor Tools
BioSolveIT
Chemical Computing Group   (New 2014)
Crelux
CrystaX Pharmaceuticals  Acquired by Oryzon Genomics
Domainex   (New 2014)
Emerald BioStructures
Exscientia   (New 2014)
Evotec
Graffinity  Acquired by NovAliX 
iNovacia  Acquired by Kancera
Infarmatik
Intellisyn (New 2014)
IOTA Pharmaceuticals
Kinetic Discovery
MEDIT
Molsoft (New 2014)
Nanotemper (New 2014)
NMR Research  (New 2014)
NovAliX
Pharma Diagnostics
Proteros 
Pyxis Discovery  (Are they still an ongoing concern?)
Red Glead  (New 2014)
Saromics (New 2014)
Schrodinger
Selcia
SensiQ  (New 2014)
Structure Based Design
Viva Biotech  (New 2014)
Zenobia Therapeutics
ZoBio

Companies
Abbvie             split from Abbott
Amgen             (New 2014)
Ansaris (previously Locus)
Ariad               (New 2014)
AstraZeneca
Astex              Acquired by Otsuka(2013)
BioLeap
Boehringer Ingelheim
Bristol Myers Squibb
Carmot Therapeutics
Constellation Pharma
Crown Biosciences 
Dart Neuroscience
Eli Lilly
Genentech (Roche)
Genzyme Acquired by Sanofi-Aventis
GlaxoSmithKline
Heptares
Johnson & Johnson 
Merck
Nerviano Medical Sciences
Novartis
Pfizer
Plexxikon    Acquired by Daiichi Sankyo (2011)
Polyphor
Roche
Sprint Bioscience
Takeda California
UCB   (New 2014)
Vernalis
Vertex

**UPDATE** 27Mar2014: added Domainex, UCB
**UPDATE2** 28May2014: added MolSoft, Ancorex

4 comments:

Anonymous said...

The Institute of Cancer Research, London - an academic college of The University of London - also conducts a lot of fragment-based discovery to support their drug design efforts with its own fragment screening library:

http://practicalfragments.blogspot.co.uk/2013/08/fragments-vs-chk2-high-concentration.html

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0065689

Anonymous said...

The founder of SynphaTec Japon is also involved in FBDD since 1997:

http://www.synphatec-japon.com

Anonymous said...

Would be good for a future post to see who is doing FBDD in academic. Just to name but a few.

Stephen Fesik - Vanderbildt
Chris Abell - Cambridge
Rob van Montford and co-workers - ICR
Damien Young - Baylor (formerly Broad Institute)
Seth Cohen - UCSD

David said...

Since you have software companies, you can add Acpharis

http://acpharis.com/technologies/atlas